Eric slosberg oncusp
WebEric Slosberg’s Post Eric Slosberg Co-Founder, Chief Development Officer, Head of Research and Development at OnCusp Therapeutics 2h Report this post ... WebSpeaker Dr. Eric Slosberg is the Co-Founder, Chief Development Officer, & Head of Research & Development at OnCusp Therapeutics. Dr. Slosberg has over 20 years of experience leading oncology drug research & development for global pharmaceutical companies. His expertise includes design of clinical development plans, execution of …
Eric slosberg oncusp
Did you know?
WebJun 30, 2024 · Slosberg has a strong track record in clinical development and medical affairs with over 20 years of experience, and led or made significant contributions to dozens of oncology clinical development programs. He has extensive professional connections with all major clinical trial centers in the U.S. WebApr 11, 2024 · CUSP06, a preclinical-stage CDH6 ADC, is composed of a proprietary antibody with high CDH6 binding affinity, a protease cleavable linker, and an exatecan payload (a potent and clinically validated ...
WebApr 11, 2024 · /PRNewswire/ -- OnCusp Therapeutics, ... as we pivot to become a clinical stage company this year" stated Eric Slosberg, PhD, Chief Development Officer and co-founder of OnCusp Therapeutics. ... WebJun 29, 2024 · Dr. Eric Slosberg, Chief Development Officer (CDO) at OnCusp, joined the founding team from Daiichi Sankyo, where he was Vice President and Global Head of …
WebDr. Eric Slosberg has over 20 years of experience leading oncology drug research and development for global pharmaceutical companies. His expertise includes design of …
WebJun 29, 2024 · Dr. Eric Slosberg, Chief Development Officer (CDO) at OnCusp, joined the founding team from Daiichi Sankyo, where he was Vice President and Global Head of …
WebFounders Andy Fu, Bing Yuan, Eric Slosberg. Operating Status Active. Company Type For Profit. OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge … trac jobs uhbristolWeb“We are very excited to present data highlighting the exciting preclinical profile of CUSP06, a differentiated, potential global second-in-class CDH6 ADC, as we pivot to become a clinical stage company this year” stated Eric Slosberg, PhD, Chief Development Officer and co-founder of OnCusp Therapeutics. About CUSP06 trac program toyotaWebApr 1, 2024 · Dr. Eric Slosberg, Chief Development Officer (CDO) at OnCusp, joined the founding team from Daiichi Sankyo, where he was Vice President and Global Head of … trac gene nameWebMar 16, 2024 · Eric Slosberg is a Co-Founder & Chief Development Officer Head of Research & Development at OnCusp based in New York City, New York. Previously, E … trac_ik_kinematics_pluginWebOnCusp Therapeutics has 3 current employee profiles, including Co-Founder and Chief Business Officer Andy Fu. Andy Fu Co-Founder and Chief Business Officer Eric Slosberg Co-Founder, Chief Development Officer, Head of Research and Development Bing Yuan Co-Founder and CEO Choose the right Crunchbase solution for you Start Your Free Trial trac jsWebJun 29, 2024 · NEW YORK, June 29, 2024 /PRNewswire/ — OnCusp Therapeutics (or “OnCusp”), a global biopharmaceutical company focused on translating cutting-edge research assets into innovative on… trac jobs uk nhs log inWeb2 days ago · "We are very excited to present data highlighting the exciting preclinical profile of CUSP06, a differentiated, potential global second-in-class CDH6 ADC, as we pivot to … trac taupo